Oral N-acetylcysteine for Retinitis Pigmentosa
Public ClinicalTrials.gov record NCT05537220. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Retinitis pigmentosa (RP) is an inherited retinal degeneration caused by one of several mistakes in the genetic code. Such mistakes are called mutations. The mutations cause degeneration of rod photoreceptors which are responsible for vision in dim illumination resulting in night blindness. After rod photoreceptors are eliminated, gradual degeneration of cone photoreceptors occurs resulting in gradual constriction of side vision that eventually causes tunnel vision. Oxidative stress contributes to cone degeneration. N-acetylcysteine (NAC) reduces oxidative stress and in animal models of RP it slowed cone degeneration. In a phase I clinical trial in patients with RP, NAC taken by month for 6 months caused some small improvements in two different vision tests suggesting that long-term administration of NAC might slow cone degeneration in RP. NAC Attack is a clinical trial being conducted at many institutions in the US, Canada, and Europe designed to determine if taking NAC for several years provides benefit in patients with RP.
Study identification
- NCT ID
- NCT05537220
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 485 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 10, 2023
- Primary completion
- Apr 30, 2029
- Completion
- Apr 30, 2030
- Last update posted
- Jun 14, 2026
2023 – 2030
United States locations
- U.S. sites
- 24
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California - Davis, Department of Ophthalmology & Vision Science | Davis | California | 95817 | — |
| University of Southern California, Keck School of Medicine | Los Angeles | California | 90089 | — |
| University of California - San Francisco, Department of Ophthalmology | San Francisco | California | 94158 | — |
| Stanford University, Byers Eye Institute | Stanford | California | 94303 | — |
| Vitreo Retinal Associates | Gainesville | Florida | 32607 | — |
| University of Florida - Jacksonville, UF Health Jacksonville | Jacksonville | Florida | 32209 | — |
| University of Miami, Bascom Palmer Eye Institute | Miami | Florida | 33136 | — |
| Emory University, Emory Eye Center | Atlanta | Georgia | 30322 | — |
| University Of Illinois At Chicago | Chicago | Illinois | 60612 | — |
| Northwestern University | Evanston | Illinois | 60208 | — |
| University of Iowa, Carver College of Medicine | Iowa City | Iowa | 52242 | — |
| Wilmer Eye Institute- Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Harvard University, Mass. Eye and Ear | Boston | Massachusetts | 02114 | — |
| University of Michigan, Kellogg Eye Center | Ann Arbor | Michigan | 48105 | — |
| University of Minnesota, Department of Ophthalmology and Visual Neurosciences | Minneapolis | Minnesota | 55455 | — |
| Mayo Clinic, Department of Ophthalmology | Rochester | Minnesota | 55905 | — |
| University of Oklahoma, Dean McGee Eye Institute | Oklahoma City | Oklahoma | 73104 | — |
| Scheie Eye Institute | Philadelphia | Pennsylvania | 19104 | — |
| Vanderbilt University, Vanderbilt Eye Institute | Nashville | Tennessee | 37211 | — |
| Retina Foundation of the Southwest | Dallas | Texas | 75231 | — |
| University of Utah, Moran Eye Center | Salt Lake City | Utah | 84132 | — |
| University of Washington, Department of Ophthalmology | Seattle | Washington | 98109 | — |
| University of Wisconsin - Madison, McPherson Eye Research Institute | Madison | Wisconsin | 53705 | — |
| Medical College of Wisconsin, The Eye Institute | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05537220, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05537220 live on ClinicalTrials.gov.